M. S. Dolima

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
CONTEXT Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS There is an urgent need for introspection and corrective actions. MATERIALS AND METHODS An online survey was conducted(More)
BACKGROUND Type 2 diabetes mellitus (Type 2 DM) has been recognized as the recent pandemic; India and China competing each other for the title-"Diabetes Capital of the World." A number of new drugs have been recently available and has lead to a boom in the clinical drug trial industry. We intend to evaluate the trend of clinical drug trials in Type 2 DM(More)
  • 1